02016nas a2200349 4500008004100000022001400041245011900055210006900174260001300243300001000256490000700266520097200273653002601245653002401271653001901295653001101314653001601325653002601341653002501367653003201392653002201424100001901446700001701465700001801482700001801500700001801518700001901536700001901555700001601574700001601590856006001606 2011 eng d a1558-253100aA highly sensitive rapid diagnostic test for Chagas disease that utilizes a recombinant Trypanosoma cruzi antigen.0 ahighly sensitive rapid diagnostic test for Chagas disease that u c2011 Mar a814-70 v583 a
Improved diagnostic tests for Chagas disease are urgently needed. A new lateral flow rapid test for Chagas disease is under development at PATH, in collaboration with Laboratorio Lemos of Argentina, which utilizes a recombinant antigen for detection of antibodies to Trypanosoma cruzi. To evaluate the performance of this test, 375 earlier characterized serum specimens from a region where Chagas is endemic were tested using a reference test (the Ortho T. cruzi ELISA, Johnson & Johnson), a commercially available rapid test (Chagas STAT-PAK, Chembio), and the PATH-Lemos rapid test. Compared to the composite reference tests, the PATH-Lemos rapid test demonstrated an optimal sensitivity of 99.5% and specificity of 96.8%, while the Chagas STAT-PAK demonstrated a sensitivity of 95.3% and specificity of 99.5%. These results indicate that the PATH-Lemos rapid test shows promise as an improved and reliable tool for screening and diagnosis of Chagas disease.
10aAntibodies, Protozoan10aAntigens, Protozoan10aChagas Disease10aHumans10aImmunoassay10aPoint-of-Care Systems10aRecombinant Proteins10aSensitivity and Specificity10aTrypanosoma cruzi1 aBarfield, C, A1 aBarney, R, S1 aCrudder, C, H1 aWilmoth, J, L1 aStevens, D, S1 aMora-Garcia, S1 aYanovsky, M, J1 aWeigl, B, H1 aYanovsky, J uhttps://www.microfluidicsciences.com/drupal/?q=node/212